NEW YORK CITY, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), (the "Company"), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease, today announced the appointment of Greg Madison as Executive Vice President and Chief Operating Officer. In this role, Mr. Madison will lead the build-out of the commercial organization and related functions to support a potential Zerenex™ product launch in the United States and internationally. The Company's New Drug Application for Zerenex (ferric citrate coordination complex), an oral, ferric iron-based compound, is currently under review by the FDA with an assigned Prescription Drug User Fee Act (PDUFA) goal date of June 7, 2014. With Mr. Madison's appointment, Keryx will establish an office in the Boston area.
"We believe that Mr. Madison's track record of success in leadership roles spanning the various aspects of product launch and sales in the renal space will be invaluable to the Company as we prepare for the potential launch of Zerenex. We are thrilled to welcome Greg to the Company and look forward to leveraging his broad commercial expertise," said Ron Bentsur, CEO of Keryx Biopharmaceuticals.
Daniel P. Regan, a member of the Company's Board of Directors, commented, "I had the privilege of working with Greg for several years, including at Genzyme/Sanofi, where in 2010 he succeeded me as global head of the Renal division. I believe that Mr. Madison has a strong understanding of the pillars of a successful launch and product commercialization and proven execution capabilities of such strategies."Mr. Madison joins the Company from AMAG Pharmaceuticals (Nasdaq:AMAG), where he served as the Executive Vice President and Chief Commercial Officer. Prior to AMAG, Mr. Madison spent 12 years at Genzyme/Sanofi developing extensive commercial and general management expertise as he progressed into roles of increasing responsibilities and leadership, culminating in his most recent role as Vice President and General Manager of the Renal division. In this role, Mr. Madison led a global organization with three marketed products in 76 countries and drove top-line growth, with combined revenues exceeding $1 billion. Mr. Madison's prior experience in the Renal division included serving as vice president and general manager of the U.S. business; vice president of U.S. sales; and vice president of U.S. marketing where he led all pre-launch preparation for Renvela ®, now the leading phosphate binder in the U.S. market. During his tenure with Genzyme, Mr. Madison also had roles in sales management, training, managed markets and reimbursement. Prior to joining Genzyme, Mr. Madison spent five years at Jannsen Pharmaceuticals in sales and sales management roles, and began his career in the pharmaceutical industry in sales with Wyeth-Ayerst. He holds a Bachelor of Business Administration in Finance from the University of Massachusetts, Amherst. "I am pleased to join Keryx during this very important time in the Company's development. There are a multitude of patients who suffer from the devastating effects of hyperphosphatemia and iron deficiency anemia, and are in need of effective new treatment options," stated Mr. Madison. "Over the next several months, we will accelerate our preparation for the potential launch of Zerenex, pending regulatory approval. I look forward to building and working with our team to bring forward innovative solutions for patients and caregivers alike."